Navigation Links
Compound Reverses Huntington's Symptoms in Mice
Date:9/16/2008

Treatment slowed reduction of brain size, improved motor functioning, study finds

TUESDAY, Sept. 16 (HealthDay News) -- An experimental compound called HDACi 4b reversed Huntington's disease symptoms in mice genetically altered to develop the disease, say researchers at the Scripps Research Institute in California.

Huntington's is an inherited neurological disease that affects people's movement and thinking ability. There is no cure or treatment that can reverse or slow progression of the physical and mental deficits caused by the disease.

"We found that (HDACi 4b) can target the expression of several hundred genes in the brain and reverse the abnormalities caused by a single mutant protein. This suggests that a treatment for Huntington's disease that targets a core pathogenic mechanism might be close at hand -- closer than previously imagined," study author Elizabeth A. Thomas, an assistant professor in department of molecular biology, said in a Scripps news release.

In this study, the mice were given the compound after they first started to develop symptoms of Huntington's. The treatment slowed the loss of body weight and reduction of brain size, and improved their appearance and motor functioning.

"The benefit seen was surprising, and immensely exciting, because it suggests this compound could form the basis of truly relevant therapeutic treatment for Huntington's disease," Thomas said. "The mice that were destined to develop Huntington's disease receiving the treatment did significantly better than the mice who didn't receive the drug."

The findings were published this week in the early edition of the Proceedings of the National Academy of Sciences. The study received funding from Massachusetts-based Repligen Corp., which holds several patent applications related to HDAC (histone deacetylase) inhibitors, a class of agents that include HDACi 4b.

Other HDAC inhibitors produced some beneficial results in test animals but were deemed too toxic.

"[HDACi 4b] proved to be therapeutically superior, as well as less toxic than other HDAC inhibitors that had been tested for Huntington's disease," Thomas said.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about Huntington's disease.



-- Robert Preidt



SOURCE: Scripps Research Institute, news release, Sept. 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Coloring Compound in Fruits, Veggies May Cut Colon Cancer Risk
2. Sugary Sodas High in Diabetes-Linked Compound
3. Red wine compound shown to prevent prostate cancer
4. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
5. A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma
8. Primus Innovations and Health Robotics Launch Strategic Partnership to Accelerate Transformation in Chemotherapy Compounding
9. Cannabis Compound May Stop Metastatic Breast Cancer
10. Prostate Cancer Treatments Often Compound Existing Health Problems
11. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... specifically to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers ... alternative to dairy proteins, providing direct cost savings as well as more stable ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... and collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 ... experience for education and business. , Mirroring360 Pro enables educators, business professionals and ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... CEOs, CFOs and HR decision-makers are preparing for how his administration could impact ... will provide insight into what changes are most likely to make it through ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... a modern procedure that achieves results in a fraction of the time as ... Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with or ...
(Date:4/25/2017)... MN (PRWEB) , ... April 25, 2017 , ... Buyers ... and recreational users to dispensaries and head shops –can’t help but be heartened by ... for the tell-tale cannabis odor aptly described as “skunk smell.” At last they ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: